FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters
Directory of sites
Login
Contact
Support
Road to Brexit
Royal Family
The Trump Effect
Detained in Myanmar
North Korea Revealed
Technology
Sport
Lifestyle
Regulatory News - Americas
April 10, 2018 / 9:38 AM / 15 days ago

BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease

Reuters Staff

1 Min Read

April 10 (Reuters) - GB Sciences Inc:

* BASED THERAPY FOR PARKINSON’S DISEASE

* EXPECTS TO COMMENCE ITS FIRST-IN-HUMAN TRIAL IN EARLY 2019

* COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.